KURA
KURA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
6
$1.26M
Total Volume
$1.26M
6 transactions
Net Activity
$1.26M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Leoni Mollie
Chief Medical Officer
$440K total
Powl Brian T.
Chief Commercial Officer
$345K total
Burrows Francis
Chief Scientific Officer
$225K total
Ford Kathleen
COO
$112K total
Bair Teresa Brophy
GC
$89K total
Quick Actions
KURA has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at KURA (KURA) engaged in a total of 6 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 6 were sales. The total volume of insider trading reached $1.26M.
The net insider activity for KURA shows a net selling bias of $1.26M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Leoni Mollie (Chief Medical Officer), who traded 41.3K shares valued at $440K on Sep 28, 2026.
After selling 448 shares, Brian T. Powl held 112,817 Kura Oncology (KURA) shares directly.
Kura Oncology CCO Brian Powl sells $3,256 in shares By Investing.com
Chairman of Kura Oncology Picks Up 16% More Stock
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Insider Stock Purchases: November 17, 2026
Kura Sushi USA (NASDAQ:KRUS) Stock Rating Lowered by Northcoast Research
FAQs About KURA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for KURA.